Left ventricular hypertrophy as a surrogate end-point in hypertension

Clinical and Experimental Hypertension

Volumn 21, Issue 5-6, 1999, Pages 583-593

  Devereux, Richard B ^a   Okin, Peter M ^a   Roman, Mary J ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

Echocardiography; Hypertension; Hypertrophy; Left ventricle; Prognosis

Indexed keywords

CONFERENCE PAPER; DISEASE COURSE; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INCIDENCE; MORBIDITY; PROGNOSIS;

EID: 0032769155     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909060991     Document Type: Conference Paper

References (37)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
2. Bikkina M, Levy D, Evans JC et al: Left ventricular mass and the risk of stroke in an elderly cohort. The Framingham Heart Study. JAMA. 1994;272:33-36.
3. Koren MJ, Devereux RB, Casale PN, Savage DD, Laragh JH: Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med. 1991;114:345-352.
4. Mensah GA, Pappas TW, Koren MJ, Ulin RJ, Laragh JH, Devereux RB: Comparison of classification of hypertension severity by blood pressure level and World Health Organization criteria for prediction of concurrent cardiac abnormalities and subsequent complications in essential hypertension. J Hypertens. 1993;11:1433-1444.
5. Bolognese L, Dellavese P, Rossi L, Sarasso G, Bongo AS, Scianaro MC: Prognostic value of left ventricular mass in uncomplicated acute myocardial infarction and one-vessel coronary artery disease. Am J Cardiol. 1994;73:1-5.
6. Liao Y, Cooper RS, McGee DL, Mensah GA, Ghali JK: The relative effects of left ventricular hypertrophy, coronary artery disease, and ventricular dysfunction on survival among black adults. JAMA. 1995;273:1592-1597.
7. Liao Y, Cooper RS, Durazu-Arvizu R, Mensah GA, Ghali JK: Prediction of mortality risk by different methods of indexing for left ventricular mass. J Am Coll Cardiol. 1997;29:641-647.
8. Koren MJ, Ulin RJ, Laragh JH, Devereux RB: Reduction of left ventricular mass during treatment of essential hypertension is associated with improved prognosis. Am J Hypertens. 1991;4:1A.
9. Yurenev AP, Dyakonova HG, Novikov ID, et al: Management of essential hypertension in patients with different degrees of left ventricular hypertrophy. Multicenter trial. Am J Hypertens 1992;5:182s-189s.
10. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation. 1994;90:1786-1793.
11. Muiesan ML, Salvetti M, Rizzoni D, Castellano M, Donato F, Agabiti-Rosei E: Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens. 1995;13:1091-1105.
12. Verdecchia P, Schillaci G, Borgioni C, et al: Prognostic value of serial changes in left ventricular mass in essential hypertension. (Abstr). Am J Hypertens. 1997;10:25A.
13. Devereux RB, Agabiti-Rosei E, Dahlof B, et al: Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trials. J Hypertens 1996;14 (Suppl 2):s95-s102.
14. Devereux RB, Okin PM, Roman MJ: Preclinical cardiovascular disease and surrogate end-points in hypertension: does race influence target organ damage independent of blood pressure? Ethnicity Dis 1998;8:138-148.
15. Sutherland JE, Gazes PC, Keil JE, Gilbert GE, Knapp RG: Electrocardiographic abnormalities and 30-year mortality among white and black men of the Charleston Heart Study. Circulation. 1993;88:2685-2692.
16. Breslin DJ, Gifford RW Jr, Fairbairn JF II: Essential hypertension: a twenty year follow-up study. Circulation. 1966;33:87-97.
17. Sokolow M, Perloff D: Prognosis of essential hypertension treated conservatively. Circulation. 1961;23:697-713.
18. Sullivan JM, Vander Zwaag R, El-Zecky F, Ramanathan KB, Mirvis DM: Left ventricular hypertrophy: Effect on survival. J Am Coll Cardiol. 1993;22:508-513.
19. Kannel WB, Abbott RD: A prognostic comparison of asymptomatic left ventricular hypertrophy and unrecognized myocardial infarction. Am Heart J. 1986;111:391-397.
20. MacMahon S, Collins G, Rautaharju P, et al for the Multiple Risk Factor Intervention Trial Research Group. Electrocardiographic left ventricular hypertrophy and effects of drug therapy in the Multiple Risk Factor Intervention Trial. Am J Cardiol 1989;6:202-210.
21. Isles CG, Walker LV, Beevers DG, et al: Mortality in the Glasgow blood pressure clinic. J Hypertens. 1987;4:141-156.
22. Casale PN, Devereux RB, Milner M, et al: Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med. 1986;105:173-178.
23. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP: Left ventricular mass and incidence of coronary heart disease in an elderly cohort: The Framingham Study. Ann Intern Med. 1989;110:101-108.
24. Quinones MA, Weiner DH, Shelton BJ, et al: for the SOLVD Investigators: Echocardiographic predictors of one-year clinical outcome in the Study of Left Ventricular Dysfunction (SOLVD) Trial and Registry: A study of 1,172 patients. (abstr) Circulation. 1993; 90 (Suppl I):I-304.
25. Silberberg JS, Barre PE, Prichard SS, Sniderman AD: Impact of left ventricular hypertrophy on survival in end-stage renal disease. Kidney Int. 1989;36:286-290.
26. Parfrey PS, Harnett JD, Griffiths SM, et al: The clinical course of left ventricular hypertrophy in dialysis patients. Nephron. 1990;55:114-120.
27. Aronow WS, Epstein S, Koenigsberg M, Schwartz KS: Usefulness of echocardiographic left ventricular hypertrophy, ventricular tachycardia and complex ventricular arrhythmias in predicting ventricular fibrillation or sudden death in elderly patients. Am J Cardiol. 1988;62:1124-1125.
28. Koren MJ, Savage DD, Casale PN, Laragh JH, Devereux RB: Changes in left ventricular mass predict risk in essential hypertension. Circulation. 1990;82(Suppl III):III-29.
29. Devereux RB, Alonso DR, Lutas EM, et al: Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-458.
30. Yurenev AP, de Quattro V, Devereux RB: Hypertensive heart disease: Relationship of silent ischemia to coronary artery disease and left ventricular hypertrophy. Am Heart J. 1990;120:928-933.
31. Devereux RB, Dahlof B: Requirements for an informative trial of left ventricular hypertrophy regression. J Hum Hypertens. 1994;8:735-739.
32. Devereux RB, Dahlof B, Levy D, Pfeffer MA: Comparison of enalapril vs nifedipine to decrease left ventricular hypertrophy in systemic hypertension (The PRESERVE Trial). Am J Cardiol. 1996;78:61-65.
33. Dahlof B, Devereux R, de Faire U, et al: The Losartan Intervention for Endpoint reduction (LIFE) Study in Hypertension. Rationale, design and methods. Am J Hypertens. 1997; 10:705-713.
34. Devereux RB, Bella MJ, Dahlof B, Gerdts E, Niemenen M, Nielsen J, Papademetriou V for the LIFE Study Group: Left ventricular geometry and function in hypertensive patients with ECG left ventricular hypertrophy: The LIFE Trial. J Am Coll Cardiol 1998; 31:376A.
35. Bond G, et al: ELSA (European Lacidipine Study on Atherosclerosis). J Cardiovasc Pharmacol. 1994;23(Suppl 5):s85-s87.
36. Liebson PR, Grandits G, Prineas R, et al: Echocardiographic correlates of left ventricular structure among 844 mildly hypertensive men and women in the Treatment of Mild Hypertension Study (TOMHS). Circulation. 1993:87:476-486.
37. Devereux RB, Alderman MH: Role of preclinical cardiovascular disease in the evolution from risk factor exposure to clinical morbid event. Circulation. 1993; 88:1444-1455.